| Title | A Pilot Study of Quality of Life of Patients with Hormone-refractory Prostate Cancer after Gene Therapy. | | Author(s) | Terao S, Shirakawa T, Acharya B, Miyata M, Hinata N, Tanaka K, Takenaka A, Hara I, Naoe M, Fuji K, Okegawa T, Higashihara E, Kamidono S, Fujisawa M, Gotoh A | | Institution | Laboratory of Cell and Gene Therapy Institute for advanced Medical Sciences, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nisinomiya Hyogo 663-8501, Japan. gotoh@hyo-med.ac.jp. | | Source | Anticancer Res 2009 May; 29(5):1533-7. | | Abstract | BACKGROUND: The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC).
PATIENTS AND METHODS: The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28. A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25).
RESULTS: The scores of all items significantly improved along with the total score. Further, bodily pain was significantly reduced on day 28. Moreover, the rate of change in the serum prostate-specific antigen levels from day 0 to day 28 was significantly correlated with the rate of change in bodily pain.
CONCLUSION: In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19443362 |
|
